Placebo to vaniprevir — Competitive Intelligence Brief

Placebo to vaniprevir (Placebo to vaniprevir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor. Area: Infectious Diseases.

phase 3 Protease inhibitor NS3/4A protease Infectious Diseases Small molecule

Target snapshot

Placebo to vaniprevir (Placebo to vaniprevir) — Merck Sharp & Dohme LLC. Vaniprevir is a protease inhibitor that targets the hepatitis C virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo to vaniprevir TARGET	Placebo to vaniprevir	Merck Sharp & Dohme LLC	phase 3	Protease inhibitor	NS3/4A protease
Grazaoprevir/Elbasavir	Grazaoprevir/Elbasavir	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin	paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin	American Research Corporation	marketed	HCV protease inhibitor / NS5A inhibitor / polymerase inhibitor combination	HCV NS3/4A protease, NS5A protein, NS5B polymerase
Simeprevir + Sofosbuvir	Simeprevir + Sofosbuvir	Federal University of São Paulo	marketed	Antiviral combination (protease inhibitor + nucleotide polymerase inhibitor)	HCV NS3/4A protease and HCV NS5B RNA-dependent RNA polymerase
ABT450r-ABT267-ABT333 +/- Ribavirin	ABT450r-ABT267-ABT333 +/- Ribavirin	Ottawa Hospital Research Institute	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease, NS5A protein, NS5B polymerase
Sofosbuvir + Simeprevir	Sofosbuvir + Simeprevir	University of California, San Francisco	marketed	Antiviral combination (nucleotide polymerase inhibitor + protease inhibitor)	HCV NS5B polymerase and NS3/4A protease
Post-transplant Grazoprevir and Elbasvir	Post-transplant Grazoprevir and Elbasvir	University of Maryland, Baltimore	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor class)

1. Pfizer · 4 drugs in this class
2. French National Agency for Research on AIDS and Viral Hepatitis · 4 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. Christopher J. McLeod · 1 drug in this class
5. Hoffmann-La Roche · 1 drug in this class
6. Janssen R&D Ireland · 1 drug in this class
7. Janssen-Cilag International NV · 1 drug in this class
8. Johns Hopkins University · 1 drug in this class
9. Medical Research Council · 1 drug in this class
10. Pfizer Inc. · 1 drug in this class